Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

BACKGROUND: Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system. OBJECTIVES: An existing Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban and apixaban, each compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowrin, Kevin, Briere, Jean-Baptiste, Levy, Pierre, Millier, Aurélie, Tardu, Jean, Toumi, Mondher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482848/
https://www.ncbi.nlm.nih.gov/pubmed/32944199
http://dx.doi.org/10.1080/20016689.2020.1782164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482848/
https://www.ncbi.nlm.nih.gov/pubmed/32944199
http://dx.doi.org/10.1080/20016689.2020.1782164

Ejemplares similares